{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:35:36Z","timestamp":1789932936394,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.vaccine.2017.10.066","type":"journal-article","created":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T13:31:12Z","timestamp":1509197472000},"page":"6990-7000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII"],"prefix":"10.1016","volume":"35","author":[{"given":"Takayuki","family":"Shiratsuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvashi","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiroh","family":"Iwanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Yuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriya","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.10.066_b0005","unstructured":"WHO World malaria report 2014. <http:\/\/www.who.int\/malaria\/publications\/world_malaria_report_2014\/>."},{"key":"10.1016\/j.vaccine.2017.10.066_b0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS, S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"RTS,S Clinical Trials Partnership","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.10.066_b0015","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS, S\/AS01 malaria vaccine in African infants","volume":"367","author":"RTS,S Clinical Trials Partnership","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.10.066_b0020","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.4049\/jimmunol.165.3.1453","article-title":"The complexity of protective immunity against liver-stage malaria","volume":"165","author":"Doolan","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.10.066_b0025","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1600-065X.2008.00671.x","article-title":"Protective CD8 T cells against Plasmodium liver stages: immunobiology of an \u201cunnatural\u201d immune response","volume":"225","author":"Overstreet","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2017.10.066_b0030","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.exppara.2009.11.009","article-title":"A retrospective evaluation of the role of T cells in the development of malaria vaccine","volume":"126","author":"Tsuji","year":"2010","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2017.10.066_b0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1084\/jem.156.1.20","article-title":"Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax","volume":"156","author":"Nardin","year":"1982","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.10.066_b0040","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1086\/651025","article-title":"Further analysis of correlates of protection from a phase 2a trial of the falciparum malaria vaccines RTS, S\/AS01B and RTS, S\/AS02A in malaria-naive adults","volume":"201","author":"Olotu","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.066_b0045","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nature05361","article-title":"The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites","volume":"444","author":"Kumar","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.10.066_b0050","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1073\/pnas.90.11.5214","article-title":"Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria","volume":"90","author":"Li","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.10.066_b0055","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.4049\/jimmunol.158.3.1268","article-title":"Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria","volume":"158","author":"Rodrigues","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.10.066_b0060","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1128\/JVI.72.8.6907-6910.1998","article-title":"Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice","volume":"72","author":"Tsuji","year":"1998","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.066_b0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.20041526","article-title":"Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model","volume":"201","author":"Tao","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.10.066_b0070","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1016\/j.vaccine.2015.03.039","article-title":"Induction of CD8(+) T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine","volume":"33","author":"Pearson","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.066_b0075","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/1475-2875-8-312","article-title":"Immunological mechanisms underlying protection mediated by RTS, S: a review of the available data","volume":"8","author":"Moorthy","year":"2009","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2017.10.066_b0080","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0165-2478(90)90092-5","article-title":"Peptide-primed CD4+ cells and malaria sporozoites","volume":"25","author":"Del Giudice","year":"1990","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2017.10.066_b0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/expr.1996.0108","article-title":"Plasmodium yoelii: peptide immunization induces protective CD4+ T cells against a previously unrecognized cryptic epitope of the circumsporozoite protein","volume":"84","author":"Takita-Sonoda","year":"1996","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2017.10.066_b0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/14760584.2.2.231","article-title":"Development of RTS, S\/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant","volume":"2","author":"Gar\u00e7on","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.10.066_b0095","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jiw244","article-title":"Safety and high level efficacy of the combination malaria vaccine regimen of RTS, S\/AS01B with chimpanzee adenovirus 63 and modified vaccinia ankara vectored vaccines expressing ME-TRAP","volume":"214","author":"Rampling","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.066_b0100","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/infdis\/jiw237","article-title":"Fractional third and fourth dose of RTS, S\/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study","volume":"214","author":"Regules","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.066_b0105","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1172\/JCI39812","article-title":"Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice","volume":"120","author":"Shiratsuchi","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2017.10.066_b0110","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.vaccine.2010.12.040","article-title":"Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice","volume":"29","author":"Palma","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.066_b0115","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1128\/IAI.02626-14","article-title":"A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys","volume":"83","author":"Karen","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.10.066_b0120","doi-asserted-by":"crossref","first-page":"e0154819","DOI":"10.1371\/journal.pone.0154819","article-title":"A plasmodium promiscuous T cell epitope delivered within the Ad5 Hexon protein enhances the protective efficacy of a protein based malaria vaccine","volume":"11","author":"Fonseca","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.10.066_b0125","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/0264-410X(94)90337-9","article-title":"Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application","volume":"12","author":"de Oliveira","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.066_b0130","first-page":"29","article-title":"In vitro expression and in vivo immunogenicity of Plasmodium falciparum pre-erythrocytic stage DNA vaccines","volume":"2","author":"Hedstrom","year":"1998","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.vaccine.2017.10.066_b0135","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4049\/jimmunol.159.3.1362","article-title":"Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein","volume":"159","author":"Calvo-Calle","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.10.066_b0140","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.4049\/jimmunol.169.12.6681","article-title":"Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein","volume":"169","author":"Persson","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.10.066_b0145","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12936-016-1248-z","article-title":"A highly infectious Plasmodium yoelii parasites, bearing Plasmodium falciparum circumsporozoite protein","volume":"15","author":"Zhang","year":"2016","journal-title":"Malaria J."},{"key":"10.1016\/j.vaccine.2017.10.066_b0150","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/JVI.56.2.439-448.1985","article-title":"Molecular composition of the adenovirus type 2 virion","volume":"56","author":"van Oostrum","year":"1985","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.10.066_b0155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0968-0004(98)01336-X","article-title":"PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization","volume":"24","author":"Nakai","year":"1999","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.vaccine.2017.10.066_b0160","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.vaccine.2015.12.074","article-title":"Status of vaccine research and development of vaccines for malaria","volume":"34","author":"Birkett","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.066_b0165","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS, S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.066_b0170","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/341323a0","article-title":"Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria","volume":"341","author":"Romero","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.10.066_b0175","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/intimm\/3.6.579","article-title":"CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria","volume":"3","author":"Rodrigues","year":"1991","journal-title":"Int Immunol"},{"key":"10.1016\/j.vaccine.2017.10.066_b0180","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/330664a0","article-title":"Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites","volume":"330","author":"Schofield","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.10.066_b0185","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1073\/pnas.85.2.573","article-title":"CD8+ T cells (cytotoxic\/suppressors) are required for protection in mice immunized with malaria sporozoites","volume":"85","author":"Weiss","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.10.066_b0190","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1084\/jem.180.1.353","article-title":"Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells","volume":"180","author":"Seguin","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.10.066_b0195","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1084\/jem.172.5.1353","article-title":"CD4+ cytolytic T cell clone confers protection against murine malaria","volume":"172","author":"Tsuji","year":"1990","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.10.066_b0200","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.4049\/jimmunol.151.5.2690","article-title":"The role of CD4+ T cells in immunity to malaria sporozoites","volume":"151","author":"Weiss","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.10.066_b0205","doi-asserted-by":"crossref","first-page":"e88205","DOI":"10.1371\/journal.pone.0088205","article-title":"An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8+ T cells in mice","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.10.066_b0210","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1016\/j.vaccine.2016.08.006","article-title":"Human CD8+ T cells mediate protective immunity induced by a human malaria vaccine in human immune system mice","volume":"34","author":"Li","year":"2016","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T18:32:38Z","timestamp":1693161158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17314743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":42,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0264410X17314743"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.066","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}